Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

Overview

Journal Curr Diab Rep

Publisher Current Science

Specialty Endocrinology

Date 2017 Oct 29

PMID 29080075

Citations 6

Authors

Magnus F Grondahl

Damien J Keating

Tina Vilsboll

Filip K Knop

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Hyperglucagonemia contributes significantly to hyperglycemia in type 2 diabetes and suppressed glucagon levels may increase the risk of hypoglycemia. Here, we give a brief overview of glucagon physiology and the role of glucagon in the pathophysiology of type 2 diabetes and provide insights into how antidiabetic drugs influence glucagon secretion as well as a perspective on the future of glucagon-targeting drugs.

Recent Findings: Several older as well as recent investigations have evaluated the effect of antidiabetic agents on glucagon secretion to understand how glucagon may be involved in the drugs' efficacy and safety profiles. Based on these findings, modulation of glucagon secretion seems to play a hitherto underestimated role in the efficacy and safety of several glucose-lowering drugs. Numerous drugs currently available to diabetologists are capable of altering glucagon secretion: metformin, sulfonylurea compounds, insulin, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 inhibitors and amylin mimetics. Their diverse effects on glucagon secretion are of importance for their individual efficacy and safety profiles. Understanding how these drugs interact with glucagon secretion may help to optimize treatment.

Citing Articles

Dapagliflozin added to metformin reduces perirenal fat layer in type 2 diabetic patients with obesity.

Cuatrecasas G, de Cabo F, Coves M, Patrascioiu I, Aguilar G, Cuatrecasas G Sci Rep. 2024; 14(1):10832.

PMID: 38734755 PMC: 11088615. DOI: 10.1038/s41598-024-61590-6.

Know your neighbors: microbial recognition at the intestinal barrier and its implications for gut homeostasis and inflammatory bowel disease.

Iyer K, Erkert L, Becker C Front Cell Dev Biol. 2023; 11:1228283.

PMID: 37519301 PMC: 10375050. DOI: 10.3389/fcell.2023.1228283.

Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.

Chai S, Zhang R, Zhang Y, Carr R, Zheng Y, Rajpathak S Front Endocrinol (Lausanne). 2022; 13:994944.

PMID: 36313782 PMC: 9597445. DOI: 10.3389/fendo.2022.994944.

Molecular link between dietary fibre, gut microbiota and health.

Kumar J, Rani K, Datt C Mol Biol Rep. 2020; 47(8):6229-6237.

PMID: 32623619 DOI: 10.1007/s11033-020-05611-3.

Establishing Boundaries: The Relationship That Exists between Intestinal Epithelial Cells and Gut-Dwelling Bacteria.

OCallaghan A, Corr S Microorganisms. 2019; 7(12).

PMID: 31818022 PMC: 6956261. DOI: 10.3390/microorganisms7120663.

References

Raskin P, Allen E, Hollander P, Lewin A, Gabbay R, Hu P . Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005; 28(2):260-5. DOI: 10.2337/diacare.28.2.260. View

Holst J, Holland W, Gromada J, Lee Y, Unger R, Yan H . Insulin and Glucagon: Partners for Life. Endocrinology. 2017; 158(4):696-701. PMC: 6061217. DOI: 10.1210/en.2016-1748. View

Dupre J, Behme M, McDonald T . Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab. 2004; 89(7):3469-73. DOI: 10.1210/jc.2003-032001. View

Dunning B, Foley J, Ahren B . Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia. 2005; 48(9):1700-13. DOI: 10.1007/s00125-005-1878-0. View

de Heer J, Rasmussen C, Coy D, Holst J . Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia. 2008; 51(12):2263-70. DOI: 10.1007/s00125-008-1149-y. View

Goldenberg R, Verma S, Perkins B, Gilbert J, Zinman B . Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?. Can J Diabetes. 2016; 41(1):6-9. DOI: 10.1016/j.jcjd.2016.08.001. View

OHNEDA A, Ishii S, Horigome K, Yamagata S . Glucagon response to arginine after treatment of diabetes mellitus. Diabetes. 1975; 24(9):811-9. DOI: 10.2337/diab.24.9.811. View

Elayat A, El-Naggar M, Tahir M . An immunocytochemical and morphometric study of the rat pancreatic islets. J Anat. 1995; 186 ( Pt 3):629-37. PMC: 1167020. View

Shah P, Vella A, Basu A, Basu R, Schwenk W, Rizza R . Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000; 85(11):4053-9. DOI: 10.1210/jcem.85.11.6993. View

10.

Inokuchi A, Oomura Y, Nishimura H . Effect of intracerebroventricularly infused glucagon on feeding behavior. Physiol Behav. 1984; 33(3):397-400. DOI: 10.1016/0031-9384(84)90160-4. View

11.

Owen M, Doran E, Halestrap A . Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000; 348 Pt 3:607-14. PMC: 1221104. View

12.

Damond N, Thorel F, Moyers J, Charron M, Vuguin P, Powers A . Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist. Elife. 2016; 5. PMC: 4871705. DOI: 10.7554/eLife.13828. View

13.

Gedulin B, Rink T, Young A . Dose-response for glucagonostatic effect of amylin in rats. Metabolism. 1997; 46(1):67-70. DOI: 10.1016/s0026-0495(97)90170-0. View

14.

EATON R . Hypolipemic action of glucagon in experimental endogenous lipemia in the rat. J Lipid Res. 1973; 14(3):312-8. View

15.

Kiec-Klimczak M, Pach D, Pogwizd M, Hubalewska-Dydejczyk A . Incretins yesterday, pleiotropic gastrointestinal hormones today:glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Recent Pat Endocr Metab Immune Drug Discov. 2011; 5(3):176-82. DOI: 10.2174/187221411797265863. View

16.

Buse J, Nauck M, Forst T, Sheu W, Shenouda S, Heilmann C . Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2012; 381(9861):117-24. DOI: 10.1016/S0140-6736(12)61267-7. View

17.

Lund A, Bagger J, Christensen M, Knop F, Vilsboll T . Glucagon and type 2 diabetes: the return of the alpha cell. Curr Diab Rep. 2014; 14(12):555. DOI: 10.1007/s11892-014-0555-4. View

18.

Fulcher G, Matthews D, Perkovic V, de Zeeuw D, Mahaffey K, Mathieu C . Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2015; 18(1):82-91. DOI: 10.1111/dom.12589. View

19.

Pernicova I, Korbonits M . Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014; 10(3):143-56. DOI: 10.1038/nrendo.2013.256. View

20.

Bagger J, Knop F, Holst J, Vilsboll T . Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes Metab. 2011; 13(11):965-71. DOI: 10.1111/j.1463-1326.2011.01427.x. View